Publications

@article{Brewster2020-ly,

title = {Metallotexaphyrins as MRI-active catalytic antioxidants for 

 neurodegenerative disease: A study on Alzheimer's disease},

author = {James T 2nd Brewster and Gregory D Thiabaud and Peter Harvey and Hadiqa Zafar and James F Reuther and Simone Dell'Acqua and Rachel M Johnson and Harrison D Root and Pedro Metola and Alan Jasanoff and Luigi Casella and Jonathan L Sessler},

year  = {2020},

date = {2020-03-01},

journal = {Chem},

volume = {6},

number = {3},

pages = {703\textendash724},

publisher = {Elsevier BV},

abstract = {The complex etiology of neurodegeneration continues to stifle 

 efforts to develop effective therapeutics. New agents 

 elucidating key pathways causing neurodegeneration might serve 

 to increase our understanding and potentially lead to improved 

 treatments. Here, we demonstrate that a water-soluble 

 manganese(II) texaphyrin (MMn) is a suitable magnetic resonance 

 imaging (MRI) contrast agent for detecting larger amyloid beta 

 constructs. The imaging potential of MMn was inferred on the 

 basis of in vitro studies and in vivo detection in Alzheimer's 

 disease C. elegans models via MRI and ICP-MS. In vitro 

 antioxidant- and cellular-based assays provide support for the 

 notion that this porphyrin analog shows promise as a therapeutic 

 agent able to mitigate the oxidative and nitrative toxic effects 

 considered causal in neurodegeneration. The present report marks 

 the first elaboration of an MRI-active metalloantioxidant that 

 confers diagnostic and therapeutic benefit in Alzheimer's 

 disease models without conjugation of a radioisotope, targeting 

 moiety, or therapeutic payload.},

keywords = {Alzheimer\'s disease, amyloid   aggregation, amyloid beta, amyloid beta modifications by ROS and   RNS, C. elegans AD models, expanded porphyrin, metalloantioxidant, MRI, neurodegeneration, texaphyrin},

pubstate = {published},

tppubtype = {article}

}